WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009133107) MODULATORS OF DOPAMINE NEUROTRANSMISSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/133107    International Application No.:    PCT/EP2009/055137
Publication Date: 05.11.2009 International Filing Date: 28.04.2009
IPC:
C07D 311/20 (2006.01), C07D 311/58 (2006.01), C07D 319/16 (2006.01), A61P 25/00 (2006.01), A61K 31/357 (2006.01)
Applicants: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE [DK/DK]; NeuroSearch A/S Pederstrupvej 93 DK-2750 Ballerup (DK) (For All Designated States Except US).
SONESSON, Clas [SE/SE]; (SE) (For US Only).
SVENSSON, Peder [SE/SE]; (SE) (For US Only).
KARLSSON, Jonas [SE/SE]; (SE) (For US Only)
Inventors: SONESSON, Clas; (SE).
SVENSSON, Peder; (SE).
KARLSSON, Jonas; (SE)
Agent: MADSEN, Inger Margrethe; (DK)
Priority Data:
PA 2008 00598 29.04.2008 DK
61/049,059 30.04.2008 US
Title (EN) MODULATORS OF DOPAMINE NEUROTRANSMISSION
(FR) MODULATEURS DE LA NEUROTRANSMISSION DE LA DOPAMINE
Abstract: front page image
(EN)The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)- methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
(FR)La présente invention concerne de nouveaux dérivés de la 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-méthanamine, utiles en tant que modulateurs de la neurotransmission de la dopamine, et plus spécifiquement en tant que stabilisateurs dopaminergiques. Dans d’autres aspects, l’invention concerne l’utilisation de ces composés dans un procédé thérapeutique et des compositions pharmaceutiques comprenant les composés de l’invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)